Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | SVP Clinical Development & Reg | December 16, 2016 | December 19, 2016 |
| Vaxxinity, Inc.VAXX · Entity 91688 | Director | October 01, 2023 | October 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 16, 2016 · Filed December 19, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby GRAT | 2,459 |
Reported balance
After 2016-05-16 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2016-05-16 · Gift · Disposed 2,459 · Balance 2,459 |
| Common StockSEC Table I · non-derivative | Indirectby GRAT | 0 |
Reported balance
After 2016-05-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2016-05-16 · Gift · Disposed 2,459 · Balance 0 |
| Common StockSEC Table I · non-derivative | Indirectby Trust for Son | 2,459 |
Reported balance
After 2016-05-16 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2016-05-16 · Gift · Acquired 2,459 · Balance 2,459 F1: By a trust for the benefit of the reporting person's son of which the reporting person's spouse is trustee. |
| Common StockSEC Table I · non-derivative | Indirectby trust for daughte | 2,459 |
Reported balance
After 2016-05-16 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2016-05-16 · Gift · Acquired 2,459 · Balance 2,459 F2: By a trust for the benefit of the reporting person's daughter of which the reporting person's spouse is trustee. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $381.92 · Expires 2026-12-16 | Direct | 5,000 |
Reported balance
After 2016-12-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-12-16 · Grant · Acquired 5,000 · Balance 5,000 F3: The stock option award vests in full one year after the date of grant. |
| Common StockSEC Table I · non-derivative | Direct | 25,714 |
Reported balance
Holding disclosure · report date 2016-12-16 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 25,714 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,674 |
Reported balance
Holding disclosure · report date 2016-12-16 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 1,674 |
Filing footnotes · ownership attribution and instrument terms
F1: By a trust for the benefit of the reporting person's son of which the reporting person's spouse is trustee.
F2: By a trust for the benefit of the reporting person's daughter of which the reporting person's spouse is trustee.
F3: The stock option award vests in full one year after the date of grant.
Vaxxinity, Inc.
Report date October 01, 2023 · Filed October 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.27 | Direct | 159,744 |
Reported balance
After 2023-10-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-10-02 · Grant · Acquired 159,744 · Balance 159,744 F1: These options were granted following the Reporting Person joining the Issuer's leadership team as Executive Vice President, Global Scientific Director, effective October 1, 2023, while remaining a member of the Issuer's board of directors. F2: These options vest in 12 equal monthly installments beginning on October 1, 2023. F3: These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted following the Reporting Person joining the Issuer's leadership team as Executive Vice President, Global Scientific Director, effective October 1, 2023, while remaining a member of the Issuer's board of directors.
F2: These options vest in 12 equal monthly installments beginning on October 1, 2023.
F3: These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2023 Filed Oct 11, 2023 21:42 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | GrantStock option (right to buy) · Derivative | 159,744 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001437749-23-028074 · rdgdoc.xml · derivative · entry 1 Powchik Peter · CIK 0001377247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,744 Underlying: Class A common stock · 159,744 shares Expires not disclosed F1 · date: These options were granted following the Reporting Person joining the Issuer's leadership team as Executive Vice President, Global Scientific Director, effective October 1, 2023, while remaining a member of the Issuer's board of directors. F2 · derivative.exercise_date: These options vest in 12 equal monthly installments beginning on October 1, 2023. F3 · derivative.expiration_date: These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates. Read SEC document |
| June 20, 2023 Filed Jun 26, 2023 18:31 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | GrantStock option (right to buy) · Derivative | 132,352 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001437749-23-018534 · rdgdoc.xml · derivative · entry 1 Powchik Peter · CIK 0001377247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,352 Underlying: Class A Common Stock · 132,352 shares Expires not disclosed F1 · date: These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation. F2 · derivative.exercise_date: These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the Issuer through the vesting date. F3 · derivative.expiration_date: These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 19:54 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | GrantStock option (right to buy) · Derivative | 129,187 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001437749-22-015778 · rdgdoc.xml · derivative · entry 2 Powchik Peter · CIK 0001377247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,187 Underlying: Class A common stock · 129,187 shares Expires not disclosed F1 · date: These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation. F2 · derivative.exercise_date: These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the issuer through the vesting date. F3 · derivative.expiration_date: These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 19:55 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | GrantStock Option (right to buy) · Derivative | 94,186 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-22-013482 · doc4.xml · derivative · entry 1 Powchik Peter · CIK 0001377247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,186 Underlying: Class A common stock · 94,186 shares Expires 2022-03-31 F1 · derivative.exercise_date: These options are subject to a three-year time-vesting schedule, with 31,395 shares vesting on the first and second anniversaries of the grant date and the remainder vesting on the third anniversary of the grant date. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000089 · edgardoc.xml · derivative · entry 7 Powchik Peter · CIK 0001377247 · SVP Clinical Development & Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2026-12-16 F3 · derivative.exercise_date: The stock option award vests in full one year after the date of grant. Read SEC document |
| May 16, 2016 Filed Dec 19, 2016 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 2,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-16-000089 · edgardoc.xml · nonDerivative · entry 4 Powchik Peter · CIK 0001377247 · SVP Clinical Development & Reg 10b5-1 filing: Not disclosed Ownership: Indirect · by trust for daughte Disclosed balance after: 2,459 F2 · ownership.nature: By a trust for the benefit of the reporting person's daughter of which the reporting person's spouse is trustee. Read SEC document |
| May 16, 2016 Filed Dec 19, 2016 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 2,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-16-000089 · edgardoc.xml · nonDerivative · entry 3 Powchik Peter · CIK 0001377247 · SVP Clinical Development & Reg 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 2,459 F1 · ownership.nature: By a trust for the benefit of the reporting person's son of which the reporting person's spouse is trustee. Read SEC document |
| May 16, 2016 Filed Dec 19, 2016 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 2,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-16-000089 · edgardoc.xml · nonDerivative · entry 2 Powchik Peter · CIK 0001377247 · SVP Clinical Development & Reg 10b5-1 filing: Not disclosed Ownership: Indirect · by GRAT Disclosed balance after: 0 Read SEC document |
| May 16, 2016 Filed Dec 19, 2016 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 2,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-16-000089 · edgardoc.xml · nonDerivative · entry 1 Powchik Peter · CIK 0001377247 · SVP Clinical Development & Reg 10b5-1 filing: Not disclosed Ownership: Indirect · by GRAT Disclosed balance after: 2,459 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.